CRIS Current Research Information System

PEA, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.820
NA - Nord America 8.681
EU - Europa 8.558
SA - Sud America 1.086
AF - Africa 298
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 29.481
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.521
SG - Singapore 3.758
IT - Italia 3.306
CN - Cina 3.177
DE - Germania 1.402
VN - Vietnam 1.201
GB - Regno Unito 1.144
BR - Brasile 805
HK - Hong Kong 800
IN - India 797
SE - Svezia 706
KR - Corea 632
NL - Olanda 444
RU - Federazione Russa 430
IE - Irlanda 286
FI - Finlandia 157
FR - Francia 157
JP - Giappone 125
CI - Costa d'Avorio 113
AR - Argentina 112
ID - Indonesia 106
UA - Ucraina 92
AT - Austria 68
CH - Svizzera 63
ZA - Sudafrica 63
CA - Canada 54
EC - Ecuador 53
ES - Italia 51
MX - Messico 44
PL - Polonia 44
BG - Bulgaria 39
PA - Panama 34
AU - Australia 33
TR - Turchia 33
SC - Seychelles 31
BD - Bangladesh 27
CL - Cile 24
CO - Colombia 24
BE - Belgio 22
PY - Paraguay 22
HR - Croazia 21
EE - Estonia 19
IQ - Iraq 17
PE - Perù 17
GR - Grecia 15
PT - Portogallo 15
JO - Giordania 14
NG - Nigeria 14
RO - Romania 14
IL - Israele 13
MA - Marocco 13
EG - Egitto 12
PK - Pakistan 12
SA - Arabia Saudita 12
TG - Togo 12
VE - Venezuela 12
IR - Iran 11
UY - Uruguay 10
TN - Tunisia 9
TW - Taiwan 9
UZ - Uzbekistan 9
CZ - Repubblica Ceca 8
DO - Repubblica Dominicana 8
LT - Lituania 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
HU - Ungheria 7
KE - Kenya 7
SK - Slovacchia (Repubblica Slovacca) 7
LV - Lettonia 6
PH - Filippine 6
TH - Thailandia 6
BO - Bolivia 5
CR - Costa Rica 5
CY - Cipro 5
RS - Serbia 5
UG - Uganda 5
DK - Danimarca 4
NP - Nepal 4
BH - Bahrain 3
GA - Gabon 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
LI - Liechtenstein 3
MN - Mongolia 3
NO - Norvegia 3
OM - Oman 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CM - Camerun 2
CV - Capo Verde 2
DM - Dominica 2
DZ - Algeria 2
GF - Guiana Francese 2
GP - Guadalupe 2
HN - Honduras 2
JM - Giamaica 2
KH - Cambogia 2
Totale 29.442
Salva come PNG Salva come JPEG
Città #
Singapore 2.406
Hefei 1.296
Southend 952
Ashburn 939
Fairfield 812
Hong Kong 786
Seoul 619
Dallas 574
Santa Clara 551
Princeton 476
Bologna 425
Woodbridge 411
Boardman 357
Milan 355
Dong Ket 354
Beijing 352
Seattle 343
Houston 330
Cambridge 300
Wilmington 289
Dublin 283
Chandler 245
Rome 230
Ho Chi Minh City 222
Ann Arbor 184
Los Angeles 180
Hanoi 157
Des Moines 152
Redondo Beach 135
Bengaluru 130
Abidjan 112
Buffalo 112
Tokyo 107
Redwood City 105
New York 92
Chicago 85
São Paulo 74
Shanghai 71
Naples 70
Turin 69
Helsinki 68
Jakarta 67
Florence 63
San Diego 62
Berlin 60
Lappeenranta 60
Genoa 53
Nuremberg 52
Munich 51
Redmond 51
Castel Maggiore 48
Frankfurt am Main 48
Nanjing 48
Tongling 44
Bremen 43
Verona 43
London 41
Medford 41
Guangzhou 38
Hangzhou 36
Jinan 36
Amsterdam 35
Bern 35
Modena 35
Vienna 35
Mumbai 34
Sofia 34
Padova 30
Paris 29
Bari 28
Saint Petersburg 28
Turku 28
Da Nang 27
Vicenza 27
Yubileyny 27
Council Bluffs 26
Falkenstein 26
Phoenix 25
The Dalles 24
Warsaw 23
Westminster 23
Zhengzhou 23
Jacksonville 22
Rio de Janeiro 22
Bühl 21
Istanbul 21
Padua 21
Toronto 21
Trieste 21
Changsha 20
Columbus 20
San Francisco 20
Tianjin 20
Buenos Aires 19
Olalla 19
Porto Alegre 19
Tappahannock 19
Ancona 18
Forlì 18
Guayaquil 18
Totale 17.756
Salva come PNG Salva come JPEG
Nome #
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: One stone for two birds? 1.161
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence 291
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients 287
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 237
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel 213
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 210
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 200
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach 184
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 174
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 172
[PK/PD profile and post-marketing surveillance of levofloxacin] 172
Enhancement of in-vitro activity of ofloxacin and gentamicin by rat serum 172
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics 172
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 168
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 165
Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis 163
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 162
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams 161
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 161
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 159
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia 156
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 155
Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel 153
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run 152
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 152
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 149
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 147
Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales 147
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow 145
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 145
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 145
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 144
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 144
Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. 143
Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales 142
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction 140
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 139
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 137
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 137
Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study 136
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. 136
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis 135
Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia? 135
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 133
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 133
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 131
The current role of glycopeptides in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts 131
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring 130
Methicillin-resistant Staphylococcus epidermidis knee prosthetic infection treatment with two-stage revision and fosfomycin–rifampin combination therapy: a case report 129
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid 129
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 129
Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections 128
Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections? 128
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. 128
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 128
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 127
Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia 127
Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections 126
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 124
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# 124
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 124
A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 124
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 123
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections 123
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients 122
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 121
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients 120
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 120
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem 119
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 119
Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections 117
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors 117
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 116
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring 114
Tocilizumab in patients with severe COVID-19: a retrospective cohort study 114
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections 114
Is it Time to Move From Intermittent to Continuous Infusion Administration of Vancomycin? 113
Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. 113
Blood concentrations and clinical effect of cyclosporin in psoriasis 113
Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice 112
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 112
β-blockers and diltiazem combination—bear in mind the risk of heart block 112
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions 111
Is the use of vancomycin doses of at least 1 g every 8 hours the only way to achieve optimal trough levels in critically ill trauma patients with pneumonia and normal renal function? 111
What does it mean: Appropriate therapy for methicillin-resistant Staphylococcus aureus? [17] 111
Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. 110
Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring? 110
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance 110
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 110
Liposome encapsulated daunorubicin (daunoxome) for acute leukemia 109
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan 108
Comparison of the antibacterial activity and synergistic activity towards antibiotics of different mammalian sera 108
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring 107
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 107
Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis 106
Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action 106
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? 106
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM) 105
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data 105
Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. 105
Totale 14.810
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.984
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.984
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.796 0 0 0 0 0 266 43 67 211 382 52 775
2021/20223.502 126 51 221 215 623 321 112 289 327 163 460 594
2022/20232.836 354 309 161 431 155 184 173 157 489 92 180 151
2023/20242.003 99 171 129 207 178 204 204 180 135 207 160 129
2024/20257.972 275 1.026 744 590 991 404 690 246 170 756 655 1.425
2025/20269.614 1.339 2.328 2.140 1.682 1.373 752 0 0 0 0 0 0
Totale 30.298